Overview
Watch this web series on Severe Asthma (2 parts) to know the evolution in the understanding of Biologics in Severe Asthma Management. Especially, Omalizumab is widely available in India and is getting acceptance increasingly due to its better clinical outcomes, safety and cost effectiveness in Severe allergic asthma management.
Faculty
Dr Roland Buhl
Professor of Medicine, Johannes Gutenberg University of Mainz Head of the Pulmonary Department at Mainz University Hospital, Germany Global Initiative for Asthma (GINA)
Dr Raja Dhar
MBBS (Cal), MD (Respiratory Medicine), MRCP (UK) MSc (Evidence Based Medicine, UK) CCT (Respiratory and General Medicine UK), FCCP (USA), Diploma in Palliative Care (Newcastle University) Certificate in Education (Deeside University)Director & HoD Pulmonology, Fortis Hospital. Director, Research & Education, National Allergy Asthma Bronchitis Institute, Kolkata, India
Dr. Deepak Talwar
MD, DTCD, DNB, FNCCP, FCCP (USA), FISDA, DM (Pulmonary & Critical Care Medicine)Pulmonary and Critical Care Medicine | Director Pulmonary, Allergy, Sleep and Critical Care | Metro Group of HospitalsResources
External Resources
Severe Asthma Conclave 2020 – A Web Series on Clinical Paradigms: Part 1
Also Read
Our Research
